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Abstract
The first objective of this study was to determine the GenoType NTM-DR assay perfor-
mance for subspecies identification in Mycobacterium abscessus complex isolates. The
second objective was to evaluate the GenoType NTM-DR assay ability to detect clarithro-
mycin and amikacin resistance in M. abscessus complex isolates compared with drug sus-
ceptibility testing (DST) and PCR sequencing of the erm(41), rrl and rrs genes. The
concordance between the GenoType NTM-DR and MLST results concerning subspecies
identification was 100%. The wild type and mutated alleles of the rrl and rrs genes were
detected by the GenoType NTM-DR assay and PCR sequencing with 100% (115/115)
agreement. Similarly, 100% concordance between GenoType NTM-DR and DST was
observed for clarithromycin and amikacin testing. Sensitivity for the detection of clarithromy-
cin and amikacin resistance was 100%. The GenoType NTM-DR assay provides a robust
and complementary tool to the gold standard methods (MLST and broth microdilution) for
subspecies identification and drug resistance detection.
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Introduction
The fast-growing Mycobacterium abscessus complex is an emerging opportunistic human
pathogen worldwide [1]. It includes three subspecies: M. abscessus subspecies abscessus, M.
abscessus subsp. massiliense, and M. abscessus subsp. bolletii [2]. The most frequent clinical
manifestation of M. abscessus complex infection is chronic lung infection, usually in elderly
women with bronchiectasis and in young adults with cystic fibrosis (CF) [3].
M. abscessus carries or acquires inducible resistance to macrolides (e.g. clarithromycin) and
aminoglycosides (e.g. amikacin) used to treat pulmonary infections. Resistance to macrolides
can be: i) constitutive (associated with point mutations at position A2058 and A2059 of the rrl
gene, a macrolide target), in all subspecies; and ii) inducible (associated with the erm(41) gene
T28 sequevar), only in M. abscessus subsp. abscessus and bolletii [4]. A single 16S ribosomal
RNA (rRNA) substitution at position 1408 in the rrs gene causes high-level aminoglycoside
resistance [4, 5]. Rapid molecular diagnosis is essential for subspecies identification and deter-
mination of the adequate antimicrobial therapy, and is now recommended in patients with CF
[3, 6].
The recently commercialized GenoType NTM-DR test (NTM-DR) (Hain, Lifescience,
Nehren, Germany) allows the rapid M. abscessus subspecies identification and simultaneously
the detection of resistance to macrolides and aminoglycosides [7–9].
This study wanted to 1) determine NTM-DR performance for subspecies identification in
M. abscessus complex isolates (compared with MLST), and 2) evaluate NTM-DR ability to
detect clarithromycin and amikacin resistance (compared with phenotypic and sequencing
analyses).
Materials and methods
Patients and mycobacteria isolates
For this study, 115 M. abscessus complex isolates (1 isolate/patient) were randomly selected
among the 176 isolates (1 isolate/patient) from respiratory samples of 176 different patients
with CF or other respiratory diseases stored at the Microbiology Laboratory, University Hospi-
tal, Montpellier (France). All M. abscessus complex isolates came from six University Hospitals
in France (Brest, Bordeaux, Montpellier, Nantes, Rouen, and Toulouse), including a Reference
Centre for CF.
Molecular analysis and drug susceptibility testing
Total DNA was extracted using GenoLyse v2.0 (Hain Lifescience, Nehren, Germany). Isolates
were assigned to the M. abscessus complex using the multiplex GenoType Mycobacterium CM
assay (Hain Lifescience Nehren, Germany), and subspecies were identified with the GenoType
NTM-DR Kit (Hain Lifescience, Nehren, Germany), the index test, according to the manufac-
turer’s recommendations. All isolates were also characterized by multilocus sequence typing
(MLST), based on eight housekeeping genes (argH, cya, glpK, gnd, murC, pgm, pta, and purH),
as previously described [10]. M. abscessus complex subspecies, allele and sequence type were
identified using the M. abscessus MLST database (http://www.pasteur.fr/recherche/genopole/
PF8/mlst/Myco-abscessus).
Resistance was assessed using the GenoType NTM-DR Kit and by phenotypic drug suscep-
tibility testing (DST), the reference method [11]. The Minimum Inhibitory Concentrations
(MICs) of clarithromycin and amikacin were evaluated using the reference broth microdilu-
tion method with Sensititre RAPMYCO microplates (Trek Diagnosis Systems). Susceptibility
and resistance were assessed according to the CLSI recommendations. High-level
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clarithromycin resistance was defined by a MIC�8 μg/ml at day 5. Inducible resistance was
defined by an increase in clarithromycin MIC from�2 μg/ml at day 5 to�8 μg/ml at day 14.
Aminoglycoside resistance was defined by MIC values�64 μg/ml [11]. Mutations in the erm
(41), rrl and rrs genes were identified by PCR and sequencing, as previously described [12, 13].
NTM-DR detects heteroresistance in mixed populations of drug-susceptible and -resistant
mycobacteria and shows the simultaneously the presence of wild type (WT) and mutant
(MUT) bands.
Statistical analyses
Based on an expected NTM-DR assay sensitivity of 96% for subspecies identification (100%
and 92% according to the manufacturer and Kehrmann et al. [7], respectively), 115 of the 176
isolates (60 M. abscessus subsp. abscessus, 47 M. M. abscessus subsp. massiliense, and 8 M.
abscessus subsp. bolletii) were needed to assess the test sensitivity with a precision of ±5%.
Results
The agreement between NTM-DR and MLST results for subspecies identification was 100%
(60/60) for M. abscessus subsp. abscessus, 100% (47/47) for. M. abscessus subsp. massiliense,
and 100% (8/8) for M. abscessus subsp. bolletii. NTM-DR sensitivity and specificity for M.
abscessus subsp. abscessus identification were 100% [95% CI: 96.2–100] and 100% [95% CI:
93.5–100].
Both NTM-DR and DST identified 59/115 (51.3%) isolates as resistant to clarithromycin:
12 (n = 7 M. abscessus subsp. abscessus and n = 5 M. abscessus subsp. massiliense) with high
resistance level and 47 (n = 39 M. abscessus subsp. abscessus and n = 8 M. abscessus subsp. bol-
letii) with inducible resistance (S1 Table). Both techniques identified six (5.2%, 6/115) isolates
resistant to aminoglycosides (n = 4 M. abscessus subsp. abscessus and n = 2 M. abscessus subsp.
massiliense) (S1 Table). Agreement was total between NTM-DR and DST results for clarithro-
mycin and aminoglycoside resistance.
NTM-DR identified rrl mutations associated with high level of resistance in the 12 isolates
with high resistance to clarithromycin (n = 4 A2058C, n = 5 A2058G, and n = 3 A2059G rrl
mutation, corresponding to the positive MUT1, MTU2 and MUT4 bands of NTM-DR, respec-
tively, (S1 Table). Among the 12 clarithromycin-resistant M. abscessus subsp. abscessus isolates,
11 showed a rrl profile without WT band and one presented a heterogeneous pattern (one WT
and one MUT1 band), suggesting the presence of a mixed population. In all 47 isolates with
inducible clarithromycin resistance, NTM-DR detected a specific erm (41) T28 sequevar band
and a WT band in the rrl gene. Finally, all 56 isolates susceptible to clarithromycin by DST
were susceptible also by NTM-DR (erm(41) C28 sequevar band and WT band in the rrl gene)
(S1 Table).
The six isolates with aminoglycoside resistance displayed the positive MUT1 band by
NTM-DR. Sequencing confirmed the presence of the A1408G rrs mutation in these isolates.
The 109 (94.8%) aminoglycoside-susceptible isolates showed a WT band by NTM-DR and
WT rrs gene sequence (S1 Table). Overall, NTM-DR and sequencing showed 100% agreement.
The concordance between NTM-DR and DST was 100% for clarithromycin and amikacin.
NTM-DR sensitivity for the detection of clarithromycin and amikacin resistance was also
100%.
Discussion
Our study showed an excellent concordance (100%) between NTM-DR and MLST results con-
cerning subspecies identification, and confirmed the high sensitivity of NTM-DR for detecting
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acquired resistance. This is higher than what reported by a recent study on 50 M. abscessus
complex isolates (92% concordance between NTM-DR and gene sequencing for subspecies
identification) [7, 14, 15]. The excellent results observed confirmed that the NTM-DR assay
seems a discriminative method for M. abscessus complex subspecies identification [7, 9, 16].
Our study showed that NTM-DR can detect acquired resistance with high sensitivity. This
test also easily detects heteroresistance, not always possible by sequencing [8]. This is crucial
for treatment decision-making, and it would be relevant to evaluate in vitro NTM-DR sensitiv-
ity for heteroresistance detection in mixed populations of drug-susceptible and -resistant
mycobacteria.
Although this is not the case for our sample, it has been reported that some isolates with
phenotypic resistance to macrolides and aminoglycoside do not carry mutations in the rrl and
rrs genes. This implies the existence of other resistance mechanisms that cannot be detected by
the NTM-DR and other commercial kits [7, 8]. For example, a modification (direct repeat
18-bp insertion in rpIV) in the ribosomal protein L4 has been recently associated with resis-
tance to macrolides [17].
Conclusion
The excellent NTM-DR performance indicates that this test is a robust and complementary
tool to MLST and broth microdilution for subspecies identification and detection of clarithro-
mycin and amikacin resistance in M. abscessus complex. NTM-DR could be used for routine
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